Product Description
Mechanisms of Action: Potassium Channel Blocker
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Kineta
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Healthy Volunteers|Psoriasis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCT02435342 | P1 |
Completed |
Psoriasis |
2015-03-01 |
|
NCT02446340 | P1 |
Completed |
Healthy Volunteers |
2014-04-01 |